EP(4) receptor as a new target for bronchodilator therapy

BACKGROUND: Asthma and chronic obstructive pulmonary disease are airway inflammatory diseases characterised by airflow obstruction. Currently approved bronchodilators such as long-acting β(2) adrenoceptor agonists are the mainstay treatments but often fail to relieve symptoms of chronic obstructive...

Descripción completa

Detalles Bibliográficos
Autores principales: Buckley, James, Birrell, Mark A, Maher, Sarah A, Nials, Anthony T, Clarke, Deborah L, Belvisi, Maria G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2011
Materias:
Airway Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3221321/
https://www.ncbi.nlm.nih.gov/pubmed/21606476
http://dx.doi.org/10.1136/thx.2010.158568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3221321/
https://www.ncbi.nlm.nih.gov/pubmed/21606476
http://dx.doi.org/10.1136/thx.2010.158568

Ejemplares similares